BioSpace News Archive

Alimera Sciences, Inc. announces that it has completed enrollment for the company’s NEW DAY clinical trial, a randomized, controlled, multi-center study designed to generate prospective data for ILUVIEN® 0.19 mg as a baseline therapy in patients diagnosed with diabetic macular edema.

Immutep Limited today announces new encouraging clinical data in 1st line non-small cell lung cancer from INSIGHT-003, an investigator-initiated Phase I trial conducted by the Frankfurt Institute of Clinical Cancer Research IKF.

Spectral Medical Inc. today reported hosting an investigator meeting in Charlotte, North Carolina on May 17 - 18, 2023.

Global research and development activity in oncology remained at historically high levels in 2022, up 22% from 2018, and the global number of patients treated with approved medicines increased at an average of 5% annually over the same period, according to a new report from the IQVIA Institute for Human Data Science on Global Oncology Trends 2023.

Masimo announced the global expansion of the HEOS platform, enabling an always-on connection to the Masimo Health secure cloud for four million devices and empowering consumers with an enhanced health tracking experience.

Lassen Therapeutics presented new preclinical and Phase I data of LASN01 for treatment of pulmonary fibrosis, at today’s American Thoracic Society (ATS) Annual Meeting being held in Washington DC.

Sarepta Therapeutics, Inc. today provided the following update on the Biologics License Application (BLA) for SRP-9001 (delandistrogene moxeparvovec), which is currently under review for the treatment of ambulant individuals with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the DMD gene.

GE HealthCare, a leader in precision care innovation, is announcing that its President and CEO Peter Arduini will present at the Jefferies Healthcare Conference in New York City on June 7, 2023 from 10:30 am to 10:55 am ET.

Enveric Biosciences, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving its EVM201 Series.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Burkhard Blank, MD, has joined the company as Executive Vice President, Research & Development and Chief Medical Officer.